Key Sessions
Sarah Snykers
Capacity is No Longer the Limiting Factor of Commercial CAR-T Production, and What Now Determines Commercial Success
Legend Biotech
Gunther Busam
Beyond Manufacturing Scale: Building Sustainable Cell & Gene Therapy Operations
Orchard Therapeutics
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Wednesday 4th November – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)
keyboard_arrow_leftSearch & Filter
search
Streams
Clear
Wednesday 4th November – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)
search
Streams
Clear
Showing 1 of 1 Streams
Exosomes Europe
09:25 - 09:30
Chairperson's Opening Remarks: Exosomes Europe 2026
- Harry Starkey - Senior Conference Producer, Informa Connect
09:30 - 10:00
Cell Line Engineering: Optimising HEK vs. MSC Hubs
- Bernd Giebel - Founder & CTO, Exosla Therapeutics
10:00 - 10:30
From Bioengineering to Scalable Manufacturing: Advancing Extracellular Vesicles for Targeted Therapeutic Applications
- Madhusudhan Reddy Bobbili - Universitätsassistent (Assistant Professor), BOKU University
Showing 1 of 1 Streams
Exosomes Europe
11:15 - 11:45
deVINCI: Engineering extracellular vesicles for tissue-selective delivery of genetic medicine
- Nazma Ilahibaks - CEO & Co-Founder, JAMA Therapeutics
11:45 - 12:15
APN-EV: Stabilising the Functional Form of Adiponectin on Engineered Extracellular Vesicles for Metabolic Disease Therapy
- Robert Mamoun - CEO, Ciloa
12:15 - 12:45
Managing Bioreactor Dynamics: Mitigating Shear Sensitivity in EV Production
- Lior Shaltiel - CEO, NurExone Biologic
Showing 1 of 1 Streams
Exosomes Europe
13:55 - 14:00
Chairperson Afternoon Remarks
- Andreia Silva - Head of Research, Exogenus Therapeutics
14:00 - 14:30
A roadmap to develop potency assay for EV-based product
- Rajeev Tawar - Associate Director, Vector and Analytical Development, Independant
14:30 - 15:00
Engineering Targeted Extracellular Vesicles for Translational Drug Delivery
- Alena Ivanova - Senior Scientist, AstraZeneca
15:00 - 15:30
[Clinical Case Study] Targeted by Nature, Powered by Innovation: EXO-CD24 Is Pioneering a New Class of Exosome-Based Therapies
- Shiran Shapira - CTO/CSO, Nano24
Showing 1 of 1 Streams
Exosomes Europe
16:15 - 16:45
Where Are Extracellular Vesicles Headed? Mapping the Future of EV Therapeutics from Lab Curiosity to Approved Class
- What is the single biggest milestone the exosome field must achieve by 2028 to maintain investor and pharma confidence?
- Native secretomes vs. engineered targeted vesicles: Which path crosses the clinical finish line first?
- Learning from the cell therapy playbook: How do we avoid the 20-year translational lag that plagued early MSCs?
- What will finally convince Big Pharma to commit to major licensing deals?
- Defining convincing clinical endpoints when exosome therapeutics operate across multiple biological mechanisms at once.
- Bernd Giebel - Founder & CTO, Exosla Therapeutics
- Alena Ivanova - Senior Scientist, AstraZeneca
- Madhusudhan Reddy Bobbili - Universitätsassistent (Assistant Professor), BOKU University
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Clear
